



## Medications for the Treatment of Diabetes

Guest Editor:

### Dr. I-Shiang Tzeng

Department of Research, Taipei  
Tzu Chi Hospital, Buddhist Tzu  
Chi Medical Foundation, New  
Taipei City 23142, Taiwan

Deadline for manuscript  
submissions:

**30 June 2024**

### Message from the Guest Editor

Diabetes is a chronic disease that develops when the pancreas cannot produce enough insulin, or when the body cannot effectively use that insulin well. Insulin medication is the most common treatment for type 1 diabetes. However, if individuals have type 2 diabetes their body can still make insulin but can no longer use it well. Most medications for type 2 diabetes are oral drugs, such as insulin, Biguanides, Dopamine-2 agonist, Dipeptidyl peptidase-4 (DPP-4) inhibitors, Glucagon-like peptide-1 receptor agonists (GLP-1 receptor agonists), Meglitinides, Sodium-glucose transporter (SGLT) 2 inhibitors, Sulfonylureas, and Thiazolidinediones. To date, the risk factors for diabetes have been identified as age, sex, body mass index, smoking status, and comorbidities, including peripheral vascular disease and hypertension. Some medications for diabetes may heighten the patient's risk of developing other diseases. Thus, new questions are emerging that need to be answered. The aim of this Special Issue is to understand the state of the art and the latest advances in the medications and treatment of diabetes, and how we may further improve the prognosis of diabetes.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)